Skip to main content
Premium Trial:

Request an Annual Quote

Advanced Biological Laboratories Receives CE Mark for SARS-CoV-2 Test

NEW YORK – Advanced Biological Laboratories announced Thursday its UltraGene Combo2Screen SARS-CoV-2 test received CE-IVD marking. 

The real-time RT-PCR test targets the N gene and E gene regions of the SARS-CoV-2 genome and requires a nasopharyngeal swab specimen. The assay is compatible with "most automatic or manual RNA extraction methods," along with qPCR instruments with at least three channels, the Luxembourg-based company said. Its turnaround time is less than two hours.

The company's US subsidiary AdvancedDx Biological Laboratories said earlier this month it had submitted the UltraGene test for Emergency Use Authorization from the US Food and Drug Administration.

On Tuesday, ABL announced it received CE-IVD marking for its its DeepChek sequencing-based assays for HIV genotyping and drug resistance testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.